

Specialty Starter Fill Drug List

To help manage the rising cost of specialty treatment, some clients have requested starter fill programs for patients. The Specialty Starter Fill program is intended to help minimize medication waste for a defined list of specialty medications with a high prevalence of side effects, poor tolerability and frequent dose or medication changes, while managing patient adherence and care, potentially improving care and providing savings for patients and clients. The program limits new-to-therapy users and non-adherent members to a two-week supply of the medication. The adjudication system monitors the member's utilization over a rolling six-month period and requires a cumulative 90-day supply of medication in order for the member to receive a full month's supply of the medication. Non-adherent members who do not meet the 90-day requirement are considered new-to-therapy users and are limited to the two-week supply of the medication.

Hematological Disorders

- **Exjade** (deferasirox)
- **Jadenu** (deferasirox)

Hepatitis B

- **Baraclude** (entecavir)
- **Epivir HBV** (lamivudine)

Oncology

- **Afinitor** (everolimus)
- **Alunbrig** (brigatinib)
- **Bosulif** (bosutinib)
- **Cabometyx** (cabozantinib s-malate)
- **Erivedge** (vismodegib)
- **Gleevec** (imatinib)
- **Inlyta** (axitinib)
- **Iressa** (gefitinib)
- **Jakafi** (ruxolitinib)
- **Lorbrena** (lorlatinib)
- **Nerlynx** (neratinib)

- **Nexavar** (sorafenib)
- **Odomzo** (sonidegib)
- **Retevmo** (selpercatinib)
- **Rubraca** (rucaparib)
- **Sprycel** (dasatinib)
- **Tagrisso** (osimertinib)
- **Talzenna** (talazoparib tosylate)
- **Tarceva** (erlotinib)
- **Targretin** (bexarotene)
- **Tasigna** (nilotinib)
- **Vitrakvi** (larotrectinib)
- **Vizimpro** (dacomitinib)
- **Votrient** (pazopanib)
- **Xalkori** (crizotinib)
- **Xtandi** (enzalutamide)
- **Zolinza** (vorinostat)
- **Zykadia** (ceritinib)
- **Zytiga** (abiraterone)

Parkinson's Disease Psychosis

- **Nuplazid** (pimavanserin)